Quite a few years ago I tested gold nanoparticles (AuNPs), which I made myself, for about two months for their purported ability to enhance mental function. Unfortunately I was not able to discern any improvement other than improved sleep.
Properly made AuNPs will be a ruby red color. Here are some images of AuNPs from a supplier :
fortislife.com/gold-nanopar...
The AuNPs I made were closest in color to the 4th vial from the left in the above link and I would describe what I made as ruby red in color and crystal clear with no obvious turbidity of the suspension. The reason I made my own AuNPs is because it is too expensive to buy from retailers and suppliers in the quantities I was consuming, which was 500 ml/day in two divided doses at 40 ppm. Here is a link to AuNPs on Amazon to give you an idea of how expensive they can be at the amount I was consuming per day :
amazon.com/MMediGOLD-ppm-Tr...
Part of the reason I chose to test AuNPs is because I had already been testing silver nanoparticles (AgNPs) that I made myself for years and finding some useable health benefits with AgNPs. The other reason I decided to test AuNPs is because of their purported anti inflammatory activities throughout the body, including the brain. Here is a link to a 2023 article discussing the anti inflammatory effects of AuNPs as might apply to Alzheimer's disease (AD) :
pubs.rsc.org/en/content/art....
Here is a relevant article quote :
' AuNPs reduce neuroinflammation by inducing macrophage polarization toward the M2 phenotype, reducing pro-inflammatory cytokine expression, blocking leukocyte adhesion, and decreasing oxidative stress. Therefore, AuNPs are gradually attracting the interest of scholars and are used for treating inflammatory diseases and drug delivery. Herein, we explored the role and mechanism of AuNPs in treating neuroinflammation in AD. The use of AuNPs for treating AD is a topic worth exploring in the future, not only to help solve a global public health problem but also to provide a reference for treating other neuroinflammatory diseases. '
The above was just to give some background on my interest in AuNPs. Today, I came across what I consider an interesting 2024 article discussing the potential use of AuNPs for PD and MS :
utsouthwestern.edu/newsroom...
Here is a relevant quote from the article :
' Together, the 24 patients had an average increase in their NAD+/NADH ratios of 10.4% compared with baseline, showing that CNM-Au8 was targeting the brain as intended. Other energetic molecules, including ATP, normalized to the group mean by the end of treatment, another potentially beneficial effect. Using a validated survey for functional outcomes in PD, researchers found that study patients with this condition reported improved “motor experiences of daily living” at one point, suggesting that taking CNM-Au8 could ameliorate functional symptoms of their disease. None of the patients experienced severe adverse side effects linked to CNM-Au8. '
The following human study further illustrates the anti inflammatory effects of AuNPs in people with arthritis :
Here is a relevant quote from the human study using AuNPs in patients with arthritis :
' The study found patients’ Knee injury and Osteoarthritis Outcome Score (KOOS) improved with statistical significance. It was reported that 71.42% of the cohort experienced improvements in their perceived knee pain and 61.22% with improvements in knee stiffness. Majority of objective measurements such as pain with range of motion and specific exercises requiring proper knee health and function did not show statistically significant improvement but did show a positive improving trend in support of AuNP supplement. Study cohort showed statistically significant improvements in two specific exercises: sit-to-stand and single-leg squat. By the end of the study, 70% of the study cohort indicated that they would continue to take the supplement even after the study concluded. '
Lastly I would like to add the following study sent to me by forum member enjoy2013
which indicated that AuNPs also showed benefit in people with ALS by decreasing all cause mortality at 12 months by 60% and potentially slowed disease progression as discussed here :
pmc.ncbi.nlm.nih.gov/articl...
AuNPs are generally considered to have a very good safety profile at therapeutic dosing levels and the results described in the above article tend to confirm that idea. AuNPs are readily available over the counter, but expensive as such. If they are able to effectively extend their research, AuNPs may qualify for insurance coverage making it much more affordable for regular use in multiple disease states while having a very good safety profile at the dosing that might be required.
Art